Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Millennium submits Velcade sNDA

MLNM submitted an sNDA for Velcade bortezomib to treat newly

Read the full 103 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE